In vitro and in vivo antibacterial activities of GV129606, a new broad- spectrum trinem

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2742-2748

  Di Modugno, Enza ^a   Broggio, Renzo ^a   Erbetti, Isabelle ^a   Lowther, John ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; GV 129606; MEROPENEM; METRONIDAZOLE; PIPERACILLIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; PRIORITY JOURNAL; SEPTICEMIA; STAPHYLOCOCCUS; STRAIN DIFFERENCE; STREPTOCOCCUS;

EID: 0030777047     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2742     Document Type: Article

References (14)

1. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
2. Di Modugno, E., I. Erbetti, L. Ferrari, G. Galassi, S. Hammond, and L. Xerri. 1994. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob. Agents Chemother. 38:2362-2368.
3. Doern, G. V., G. Pierce, and A. B. Brueggemann. 1996. In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Diagn. Microbiol. Infect. Dis. 26:39-42.
4. Finney, D. J. 1952. Probit analysis, a statistical treatment of the sigmoid response curve, 2nd ed. Cambridge University Press, London, England.
5. Jones, R. N. 1992. The current and future impact of antimicrobial resistance amongst nosocomial bacterial pathogens. Diagn. Microbiol. Infect. Dis. 15:3S-10S.
6. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3th ed., vol. 10, no. 8. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
7. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3th ed. M11-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
8. Neu, H. C. 1993. The crisis in antibiotic resistance. Science 257:1064-1073.
9. Perboni, A., B. Tamborini, T. Rossi, D. Donati, and G. Gaviraghi. 1992. Tribactams: a novel class of β-lactams, p. 21-33. In P. Bentley and R. Ponsford (ed.), Recent advances in antiinfective chemistry. Royal Society of Chemistry, London, England.
10. Sanders, C. C. 1992. β-Lactamases of Gram-negative bacteria: new challenges for new drugs. Clin. Infect. Dis. 14:1089-1099.
11. Silver, L. L., and K. A. Bostian. 1993. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob. Agents Chemother. 37:377-383.
12. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1997. MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents. Antimicrob. Agents Chemother. 41:148-155.
13. Spratt, B. G. 1994. Resistance to antibiotics mediated by target alterations. Science 264:388-393.
14. Swartz, M. N. 1994. Hospital-acquired infections: disease with increasingly limited therapies. Proc. Natl. Acad. Sci. USA 91:2420-2427.